San Francisco,9 October 2018: According to a report by Grand View Research, Inc., global antisense & RNAi therapeutics market is anticipated to value USD 1.81 billion by 2025. Growing requirement of advanced and effective therapeutics to address rising cases of chronic disorders globally is anticipated to propel demand for antisense & RNAi therapeutics. Antisense technology is likely to offer an opportunity for manipulation of gene expression for treatment of several diseases. It can be used to study gene function for disease management by regulating expression of disease-causing gene.
Continual R&D for treatment of uncommon neurodegenerative diseases such as hereditary ATTR amyloidosis can influence growth of market. Development of antisense therapeutics to overcome challenges related to unspecific modes of action and delivery-associated complications can augment market growth over next few years.
Difficulty in delivering drugs to specific site is expected to become major challenge for use of antisense and RNAi. Drug delivery to nervous tissues can be tough as the drug is supposed to pass blood-brain barrier. In addition, inevitable toxic effects of using these therapeutics can further restrict growth of market over the forecast period. It is necessary to determine right dosage and composition of antisense molecule to reduce Huntington’s disease (HD) symptoms and avoid side effects.
Access Research Report of Antisense & RNAi Therapeutics Market@ www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market
The antisense & RNAi therapeutics market can be segregated on the basis of technology, application, route of administration, and region. Based on technology, the market can be categorized into RNA interference and antisense RNA. In 2016, antisense RNA segment dominated the market and accounted for largest market share over the forecast period. Growing use of antisense oligonucleotides to treat neurodegenerative disorders is expected to fuel growth of segment. In addition, implementation of various approaches for prevention of disease onset or halting progressions can influence growth. Diseases such as spinal muscular atrophy and amyotrophic lateral sclerosis are expected to show positive results with use of antisense technology.
Based on application, the market can be classified into oncology, cardiovascular, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and other. Oncology segment is expected to contribute maximum towards growth of market over next few years. Rising cases of eradication disorders such as cancer, HIV, and other mutating viral diseases can augment use of oligonucleotide products. Growing number of clinical trials for oligonucleotide drugs are likely to exhibit growth of segment. In addition, high prevalence of significant pipeline for cancer therapies by companies and institutes can boost segment growth over the forecast period. Moreover, R&D in nanocarriers for oligonucleotide delivery can contribute well to cancer treatment. These nanoparticles can be used to reduce toxicity.
Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals
Based on route of administration, the market can be divided into pulmonary delivery, intravenous injections, intradermal injections, intraperitoneal injections, topical delivery, and other delivery methods.
Regional segmentation includes Europe, North America, Asia Pacific, Latin America, and Middle East & Africa (MEA). In North America, the market is expected to witness significant growth over the forecast period. Rising number of RNAi therapeutics currently under developmental pipeline in United States can augment growth of market. Big pharmaceutical developers are likely to enter into collaborations and licensing deals with other smaller firms to boost revenue generation. This, in turn, can fuel market growth over next few years.
Since the discovery of RNAi, there have been efforts to improve treatment methods using RNAi. However, complexities in delivery methodologies associated with RNAi is expected to slow down growth of market. Development of new nanotechnology-oriented methods are likely to re-infuse the market with growth potential during the forecast period.
Moreover, rising number of drug candidates under clinical trials are expected to show favorable results and can progress through development process. This, in turn, can augment market growth over the forecast period.
Some of the leading companies offering antisense & RNAi therapeutics are Olix Pharmaceuticals, GlaxoSmithKline Plc, Alnylam Pharmaceuticals, Benitec Biopharma Ltd., and Antisense Therapeutics Limited. These players are expected to be involved in development of RNAi therapies and platforms that can offer diagnostics, medicines, personalized treatment options for key diseases.
Access Press Release of Antisense & RNAi Therapeutics Market@ www.grandviewresearch.com/press-release/antisense-rnai-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com